Ora­sis gains FDA ap­proval for pres­by­opia eye drops, fol­low­ing in Ab­b­Vie’s foot­steps

Ora­sis Phar­ma­ceu­ti­cals has se­cured ap­proval in the US for its age-re­lat­ed blur­ry vi­sion eye drops, mark­ing the sec­ond time the FDA has green­lit a pres­by­opia treat­ment.

The OK for Qlosi comes a few days ahead of the FDA de­ci­sion dead­line, which is Sun­day. The eye drops, which can be dosed up to twice dai­ly, will be­come avail­able in the first half of next year, Ora­sis said.

Ab­b­Vie snagged the first FDA clear­ance for blur­ry vi­sion eye drops in 2021, with Vuity, but the Chica­go-area Big Phar­ma took a $770 mil­lion pre-tax im­pair­ment charge last fall when it de­cid­ed to pull back on its big sales and mar­ket­ing spend. The phar­ma gi­ant then axed a sec­ond-gen­er­a­tion pres­by­opia as­set, End­points News re­port­ed ear­li­er this year. Mean­while, oth­er com­pa­nies have can­di­dates in Phase III, in­clud­ing Vi­a­tris-part­nered Ocuphire Phar­ma, Lenz Ther­a­peu­tics and Vi­s­us Ther­a­peu­tics, which plans to file an NDA in the sec­ond half of 2024, pend­ing re­sults from an­oth­er tri­al slat­ed to read out lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER